- Home
- HYLN vs AUTL Comparison
HYLN vs AUTL Comparison
Compare HYLN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYLN
- AUTL
- Stock Information
- Founded
- HYLN 2018
- AUTL 2014
- Country
- HYLN United States
- AUTL United Kingdom
- Employees
- HYLN N/A
- AUTL N/A
- Industry
- HYLN Construction/Ag Equipment/Trucks
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HYLN Consumer Discretionary
- AUTL Health Care
- Exchange
- HYLN Nasdaq
- AUTL Nasdaq
- Market Cap
- HYLN 521.2M
- AUTL 609.4M
- IPO Year
- HYLN N/A
- AUTL 2018
- Fundamental
- Price
- HYLN $2.73
- AUTL $2.29
- Analyst Decision
- HYLN Hold
- AUTL Strong Buy
- Analyst Count
- HYLN 1
- AUTL 3
- Target Price
- HYLN $2.00
- AUTL $10.20
- AVG Volume (30 Days)
- HYLN 1.6M
- AUTL 1.8M
- Earning Date
- HYLN 02-11-2025
- AUTL 11-12-2024
- Dividend Yield
- HYLN N/A
- AUTL N/A
- EPS Growth
- HYLN N/A
- AUTL N/A
- EPS
- HYLN N/A
- AUTL N/A
- Revenue
- HYLN N/A
- AUTL $10,091,000.00
- Revenue This Year
- HYLN N/A
- AUTL $1,000.24
- Revenue Next Year
- HYLN $4,210.00
- AUTL $267.86
- P/E Ratio
- HYLN N/A
- AUTL N/A
- Revenue Growth
- HYLN N/A
- AUTL 82.71
- 52 Week Low
- HYLN $0.72
- AUTL $2.20
- 52 Week High
- HYLN $4.10
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- HYLN 41.46
- AUTL 28.90
- Support Level
- HYLN $2.88
- AUTL $2.44
- Resistance Level
- HYLN $2.92
- AUTL $2.97
- Average True Range (ATR)
- HYLN 0.21
- AUTL 0.18
- MACD
- HYLN -0.10
- AUTL -0.04
- Stochastic Oscillator
- HYLN 30.79
- AUTL 8.82
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it is also focused on mobile applications, including vehicles and marine technologies. The Company aims to offer innovative, yet practical solutions that contribute positively to the environment in the energy economy.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.